QSC RESEARCH GRADE
≥99% HPLC PurityMS ConfirmedJanoshik COAIn-House SPPS1-Region Domestic Shipping
What is Tirzepatide?
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist — the first in its class of “twincretins.” Acts simultaneously on GIPR and GLP-1R to produce synergistic effects on insulin secretion, glucagon suppression, gastric emptying delay, and appetite suppression. Oral tablet formulation for GIP/GLP-1 pathway research without injection. Research use only.
Research Applications
Dual GIP/GLP-1 Receptor Agonism
GIPR + GLP-1R simultaneous activation — synergistic vs individual receptor effects
Incretin Axis Research
GIP/GLP-1 co-signalling, cAMP pathway, beta cell insulin secretion
Metabolic & Weight Research
Energy expenditure, adipose lipolysis, appetite suppression, GIP fat storage modulation
Glucose Homeostasis
Postprandial glucose excursion, hepatic glucose output, peripheral insulin sensitivity
Twincrеtin vs Monoagonist
Tirzepatide vs GLP-1 agonists alone — additive/synergistic metabolic outcomes
Quick Specs
| Form | Tablet — 500mcg per tablet, 25-tablet bottle |
| CAS Number | 2023788-19-2 |
| Molecular Formula | C₂₂₅H₃₄₈N₄₈O₆₈ |
| Molecular Weight | ~4814 Da |
| Compound Type | Dual GIP/GLP-1 Receptor Agonist |
| Purity | ≥99% by HPLC — every batch |
| Identity | MS molecular weight confirmed — every batch |
| COA | Janoshik-independent, publicly verifiable |
| Manufacture | In-house synthesis — Qingdao, China |
| Storage | Room temperature sealed | cool, dry storage | protect from moisture |
| Shelf Life | 24 months unopened |
